GEN Exclusives

More »

GEN News Highlights

More »
Jan 11, 2012

IntelliCell Licenses SVF Manufacturing Technology to Cell-Innovations

  • Cell-Innovations will market the stromal vascular fraction (SVF) manufacturing technology of IntelliCell BioSciences in Australia and New Zealand, under a license agreement that calls for a one-time payment of $700,000 and a royalty stream of 12.5% of net sales.

    IntelliCell’s technology is a nonenzymatic method for deriving SVF containing adult stem cells from 60 cc’s of adipose tissue. According to the company, the technology generates between half billion to 1.4 billion SVF cells, about 10–20 times greater than present-day enzyme-based methods.

    Cell-Innovations and IntelliCell also say they will assist Macquarie Stem Cells, a company of Cell-Innovations director Ralph Bright, to establish IntelliCell Centers of Excellence where doctors can treat their patients.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?